Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01)

Kensei Yamaguchi; Yung-Jue Bang; Satoru Iwasa; Naotoshi Sugimoto; Min-Hee Ryu; Daisuke Sakai; Hyun Cheol Cheol Chung; Hisato Kawakami; Hiroshi Yabusaki; Jeeyun Lee; Kaku Saito; Yoshinori Kawaguchi; Takahiro Kamio; Akihito Kojima; Masahiro Sugihara; Kohei Shitara

doi:10.1200/JCO.2022.40.4_suppl.242

YUHSpace

BROWSE

0 190

Cited 0 times in

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01)

Authors: Kensei Yamaguchi ; Yung-Jue Bang ; Satoru Iwasa ; Naotoshi Sugimoto ; Min-Hee Ryu ; Daisuke Sakai ; Hyun Cheol Cheol Chung ; Hisato Kawakami ; Hiroshi Yabusaki ; Jeeyun Lee ; Kaku Saito ; Yoshinori Kawaguchi ; Takahiro Kamio ; Akihito Kojima ; Masahiro Sugihara ; Kohei Shitara